October 16, 2024 03:34 PM EDT

Bavarian Nordic's mpox vaccine was safe and spurred promising immune response in children

Max Bayer

Pharma Reporter

Bavarian Nordic’s mpox vaccine Jynneos generated a similar immune response in adolescents as it did in adults, offering encouraging results that suggest the shot would …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bavarian Nordic's mpox vaccine was safe and spurred promising immune response in children

Max Bayer

Pharma Reporter

Sign up to read this article for free.

First clinical test of RNA editing restores missing protein in genetic disease, Wave says

FDA leaders kick off rare disease hub to increase cross-center collaboration

FDA places hold on Novavax's Covid-flu and standalone influenza vaccines

Facing a critical week, Pfizer confronts an unsparing foe in Starboard

Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Bavar­i­an Nordic's mpox vac­cine was safe and spurred promis­ing im­mune re­sponse in chil­dren

Max Bayer

Pharma Reporter

Sign up to read this article for free.

First clin­i­cal test of RNA edit­ing re­stores miss­ing pro­tein in ge­net­ic dis­ease, Wave says

FDA lead­ers kick off rare dis­ease hub to in­crease cross-cen­ter col­lab­o­ra­tion

FDA places hold on No­vavax's Covid-flu and stand­alone in­fluen­za vac­cines

Fac­ing a crit­i­cal week, Pfiz­er con­fronts an un­spar­ing foe in Star­board

Q&A: Sanofi’s R&D head re­flects on his first year, a post-Dupix­ent fu­ture, and find­ing an iden­ti­ty

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

Bavarian Nordic's mpox vaccine was safe and spurred promising immune response in children

First clinical test of RNA editing restores missing protein in genetic disease, Wave says

FDA leaders kick off rare disease hub to increase cross-center collaboration

FDA places hold on Novavax's Covid-flu and standalone influenza vaccines

Facing a critical week, Pfizer confronts an unsparing foe in Starboard

Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies